Aerovate Therapeutics, Inc. (AVTE)
NASDAQ$2.47
Market Cap
$71.32M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
120 of 924
Rank in Industry
82 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
AVTE Insider Trading Activity
AVTE Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $1,549,944 | 1 | 4 |
Sells | $5,235,540 | 22 | 96 |
Related Transactions
| RA CAPITAL MANAGEMENT, L.P. | 1 | $1.55M | 0 | $0 | $1.55M | |
| GRAYZEL DAVID S. | director | 0 | $0 | 1 | $334,478 | $-334,478 |
| Verwijs Marinus | CHIEF TECHNICAL OFFICER | 0 | $0 | 4 | $599,571 | $-599,571 |
| Gillies Hunter | CHIEF MEDICAL OFFICER | 0 | $0 | 5 | $767,410 | $-767,410 |
| Eldridge George A | SEE REMARKS | 0 | $0 | 3 | $967,049 | $-967,049 |
| NOYES TIMOTHY P | CHIEF EXECUTIVE OFFICER | 0 | $0 | 4 | $993,705 | $-993,705 |
| Dake Benjamin T | SEE REMARKS | 0 | $0 | 5 | $1.57M | $-1.57M |
About Aerovate Therapeutics, Inc.
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Insider Activity of Aerovate Therapeutics, Inc.
Over the last 12 months, insiders at Aerovate Therapeutics, Inc. have bought $1.55M and sold $5.24M worth of Aerovate Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Aerovate Therapeutics, Inc. have bought $71.77M and sold $8.79M worth of stock each year.
Highest buying activity among insiders over the last 12 months: RA CAPITAL MANAGEMENT, L.P. () — $1.55M.
The last purchase of 928,110 shares for transaction amount of $1.55M was made by RA CAPITAL MANAGEMENT, L.P. () on 2024‑06‑17.
List of Insider Buy and Sell Transactions, Aerovate Therapeutics, Inc.
| 2024-06-17 | RA CAPITAL MANAGEMENT, L.P. | 928,110 0.2418% | $1.67 | $1.55M | +43.03% | |||
| 2024-06-14 | Sale | Eldridge George A | SEE REMARKS | 15,000 0.0586% | $25.03 | $375,450 | -90.45% | |
| 2024-06-14 | Sale | Verwijs Marinus | CHIEF TECHNICAL OFFICER | 10,600 0.0413% | $25.00 | $265,000 | -90.45% | |
| 2024-06-13 | Sale | Gillies Hunter | CHIEF MEDICAL OFFICER | 6,000 0.0229% | $24.50 | $147,000 | -90.40% | |
| 2024-05-17 | Sale | Gillies Hunter | CHIEF MEDICAL OFFICER | 4,000 0.0136% | $21.08 | $84,332 | -88.19% | |
| 2024-05-16 | Sale | NOYES TIMOTHY P | CHIEF EXECUTIVE OFFICER | 10,000 0.0347% | $21.58 | $215,755 | -88.91% | |
| 2024-05-02 | Sale | Verwijs Marinus | CHIEF TECHNICAL OFFICER | 1,981 0.007% | $21.02 | $41,631 | -88.19% | |
| 2024-05-01 | Sale | NOYES TIMOTHY P | CHIEF EXECUTIVE OFFICER | 11,357 0.0386% | $20.34 | $230,946 | -88.24% | |
| 2024-04-17 | Sale | Gillies Hunter | CHIEF MEDICAL OFFICER | 4,000 0.0143% | $22.38 | $89,522 | -89.02% | |
| 2024-04-17 | Sale | Dake Benjamin T | SEE REMARKS | 6,853 0.0245% | $22.37 | $153,327 | -89.02% | |
| 2024-04-16 | Sale | NOYES TIMOTHY P | CHIEF EXECUTIVE OFFICER | 10,000 0.0375% | $24.70 | $246,971 | -89.54% | |
| 2024-04-10 | Sale | Eldridge George A | SEE REMARKS | 7,500 0.0268% | $26.85 | $201,392 | -90.86% | |
| 2024-04-09 | Sale | GRAYZEL DAVID S. | director | 11,882 0.0428% | $28.15 | $334,478 | -91.19% | |
| 2024-04-01 | Sale | Eldridge George A | SEE REMARKS | 12,495 0.0455% | $31.23 | $390,208 | -91.95% | |
| 2024-04-01 | Sale | Dake Benjamin T | SEE REMARKS | 3,325 0.0124% | $31.97 | $106,317 | -91.95% | |
| 2024-04-01 | Sale | Verwijs Marinus | CHIEF TECHNICAL OFFICER | 5,300 0.0181% | $29.19 | $154,697 | -91.95% | |
| 2024-04-01 | Sale | NOYES TIMOTHY P | CHIEF EXECUTIVE OFFICER | 10,000 0.035% | $30.00 | $300,033 | -91.95% | |
| 2024-03-28 | Sale | Gillies Hunter | CHIEF MEDICAL OFFICER | 9,000 0.0322% | $29.50 | $265,500 | -91.62% | |
| 2024-03-27 | Sale | Dake Benjamin T | SEE REMARKS | 11,068 0.0393% | $27.97 | $309,519 | -91.30% | |
| 2024-03-25 | Sale | Dake Benjamin T | SEE REMARKS | 3,432 0.0129% | $28.01 | $96,119 | -90.72% |
Total: 143
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| RA CAPITAL MANAGEMENT, L.P. | 7893678 27.3379% | $19.5M | 2 | 0 | <0.0001% | |
| GRAYZEL DAVID S. | director | 14502 0.0502% | $35,819.94 | 1 | 1 | <0.0001% |
| Sofinnova Venture Partners X, L.P. | 10 percent owner | 3758686 13.0173% | $9.28M | 1 | 0 | <0.0001% |
| Katabi Maha | 3758686 13.0173% | $9.28M | 1 | 0 | <0.0001% | |
| Atlas Venture Fund XII, L.P. | 10 percent owner | 3103879 10.7496% | $7.67M | 1 | 0 | <0.0001% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$2,600,095 | 110 | 13.50% | $70.91M | |
$2,942,496 | 100 | 17.32% | $66.91M | |
$4,898,715 | 46 | 40.74% | $73.28M | |
$329,102,560 | 42 | 30.96% | $73.82M | |
$542,300 | 40 | -14.44% | $67.8M |
AVTE Institutional Investors: Active Positions
| Increased Positions | 50 | +60.24% | 8M | +29.15% |
| Decreased Positions | 33 | -39.76% | 6M | -20.04% |
| New Positions | 25 | New | 6M | New |
| Sold Out Positions | 21 | Sold Out | 5M | Sold Out |
| Total Postitions | 100 | +20.48% | 30M | +9.11% |
AVTE Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Ra Capital Management, L.P. | $22,337.00 | 31.7% | 9.19M | 0 | 0% | 2024-12-31 |
| Sofinnova Investments, Inc. | $9,134.00 | 12.96% | 3.76M | 0 | 0% | 2024-12-31 |
| Tcg Crossover Management, Llc | $5,445.00 | 7.73% | 2.24M | 0 | 0% | 2024-12-31 |
| Atlas Venture Life Science Advisors, Llc | $4,372.00 | 6.2% | 1.8M | 0 | 0% | 2024-12-31 |
| Braidwell Lp | $3,500.00 | 4.97% | 1.44M | +1M | New | 2024-12-31 |
| Logos Global Management Lp | $3,402.00 | 4.83% | 1.4M | +1M | New | 2024-12-31 |
| Vanguard Group Inc | $2,435.00 | 3.46% | 1M | -149,974 | -13.02% | 2024-12-31 |
| Blackrock, Inc. | $2,370.00 | 3.36% | 975,423 | +21,747 | +2.28% | 2024-12-31 |
| Adar1 Capital Management, Llc | $2,255.00 | 3.2% | 928,016 | +814,941 | +720.71% | 2024-12-31 |
| Allostery Investments Lp | $2,067.00 | 2.93% | 850,684 | +850,684 | New | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.